Journal
EMERGING INFECTIOUS DISEASES
Volume 24, Issue 4, Pages 746-750Publisher
CENTERS DISEASE CONTROL
DOI: 10.3201/eid2404.171509
Keywords
-
Categories
Funding
- Japan Initiative for Global Research Network on Infectious Diseases from the Japan Agency for Medical Research and Development (AMED)
- Leading Advanced Projects for Medical Innovation from AMED
- e-ASIA Joint Research Program from AMED
- Ministry of Education, Culture, Science, Sports, and Technology of Japan [16H06429, 16K21723, 16H06434]
- Center for Research on Influenza Pathogenesis - US National Institutes of Health, National Institute of Allergy and Infectious Diseases [HHSN272201400008C]
- Chugai Pharmaceuticals
- Daiichi Sankyo Pharmaceutical
- Toyama Chemical
- Tauns Laboratories, Inc.
- Tsumura Co.
- Denka Seiken Co., Ltd.
- Grants-in-Aid for Scientific Research [16H06434] Funding Source: KAKEN
Ask authors/readers for more resources
To clarify the threat posed by emergence of highly pathogenic influenza A(H7N9) virus infection among humans, we characterized the viral polymerase complex. Polymerase basic 2-482R, polymerase basic 2-588V, and polymerase acidic-497R individually or additively enhanced virus polymerase activity, indicating that multiple replication-enhancing mutations in 1 isolate may contribute to virulence.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
